Nash Trial Launch in Oct / Nov 2020 - seems a bit short and slow | CORT Message Board Posts

Corcept Therapeutics Inc

  CORT website

CORT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  3294 of 3318  at  9/9/2020 10:11:14 PM  by

i760

The following message was updated on 9/9/2020 10:24:01 PM.

 In response to msg 3293 by  BSR_Alan
view thread

Re: Nash Trial Launch in Oct / Nov 2020 - seems a bit short and slow

   
Thanks Alan.
 
FWIW it would be truly remarkable if the liver MRIs should show statistically significant reduction in liver fat in 12 wks.  NASH is off the radar because of disappointments from other biotech trials so a positive readout will wake up the usual Biotech players.  And the benign side effect profile of Corcept drugs is lot more attractive than a number of NASH candidates in trials (my assumption is Miricorlaint is same / easier to tolerate than Relacorliant, which so far is not too bad)....
 
I find it truly surprising how under owned Corcept is by Biotech specialists...absence of most of the smart names means that if Corcept is successful in any indications outside Cushing's that will drive up the next leg in valuations.  I keep my healthy core position untouched as I view the probability of that (one of oncology, anti-psy wt gain, or Nash) hitting much greater than the downside from launch of generic Mife.   Of course we all can dream of home run outcomes like hitting multiple new indications and/or delaying Teva past Rela launch in Cushing's.
 
Lastly out here on the West Coast, post COVID, the clinical trail sites are aggressively hustling for patients.  The core elective medical treatment at big centers is still not back to normal as regular folks are pushing off visits / treatments until is is really necessary.  Volumes are down 25-40% depending upon specialty area.  Expenses are up since spending for Covid wave remains high and those patients are not too profitable given the cost of resources they need.  Donors are not around and Development folks are not bringing in the budgeted $$ from gifts.  Result is budget shortfalls and thus Academic centers are ramping up spending on advertising that they are open and safe (hear a Stanford ad every day).  And they are lot more motivated to ramp up clinical trials as those are the most lucrative way to interface with a patient.   Only drug companies for clinical trials pay full list price.   Hopefully that all benefits recruitment pace of Corcept trials....for a change we might see trials getting done sooner than guidance (yes never will happen but still one can dream).
 
 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 91
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
3295 Re: Nash Trial Launch in Oct / Nov 2020 - seems a bit short and slow KJDedge 0 9/10/2020 7:56:42 AM






Financial Market Data provided by
.


Loading...